1Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 andhypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy Ⅰ: interpretation in the
2Rasillo A, Tabernero MD, Sanchez ML, et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. Cancer, 2003, 97(3):601-609.
3Avet-Loiseau H, Andree-Ashley LE, Moore D, et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization.Genes Chromosomes Cancer, 1997, 19:124-133.
4Bernasconi P, Cavigliano PM, Boni M, et al. Long-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance. Br J Haematol,2002, 118:545-549.
5Nilsson T, Hoglund M, Lenhoff S, et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age-and sexrelated differ
6Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history,immunological features, and clinical presentation. Blood, 2002,99:2185-21
7Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 2001, 97: 1566-1571.
8Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridizationdefined chromosome 13 deletion in multiple myeloma: early results of total therapy Ⅱ. Br J Haematol, 2003, 120:44-52.
9Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood, 2000, 96:1505-1511.
10Sawyer JR, Lukacs JL, Munshi N, et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood, 1998, 92:4269-4278.
3Lloveras E, Granada I, Zamora L, et al. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia [ J ]. Cancer Genet Cytogenet, 2004,148 ( 1 ) :71 -76.
4Liebisch P, D? hner H. Cytogenetics and molecular cytogenetics in multiple myeloma. Eur J Cancer,2006,42 ( 11 ) : 1520 - 1529.
6Bergsagel PL, Kuehl WM,Zhan F, et al. Cyclin D dysregulation : an early and unifying pathogenic event in multiple myeloma [ J ]. Blood,2005,106( 1 ) :296 - 303.
7Bang SM, Kim YR, Cho HI, et al. Identification of 13q deletion, trisomy 1q, and IGH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma [J]. Cancer Genet Cytogenet,2006,168(2) :124 - 132.
